CommercialPrior AuthMedium impact
Azacitidine (Vidaza®)
BCBS Tennessee·TN · Oncology, Hematology, Internal Medicine·Medical Policy
Effective date
Sep 30, 2026
We identified it
Jul 17, 2026
Summary
BlueCross BlueShield of Tennessee has issued a new medical policy for Azacitidine (Vidaza®) effective 9/30/2026 establishing coverage criteria for six oncologic indications: myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), accelerated/blast phase myeloproliferative neoplasm, blastic plasmacytoid dendritic cell neoplasm (BPDCN), MDS/MPN overlap neoplasms, and peripheral T-cell lymphoma (PTCL). All covered indications require prior authorization for 12-month periods, with continuation therapy authorized upon reauthorization if no unacceptable toxicity or disease progression occurs. DO NOT IMPLEMENT until 9/30/26.
Action Required
Before 9/30/2026: (1) Billing team must configure prior authorization requirements in billing system for all Azacitidine (Vidaza®) claims to require 12-month authorization periods for the six covered indications listed in policy. (2) Update claim submission protocols to route Azacitidine claims for prior authorization approval before processing. (3) Providers must document one of the six covered indications and clinical justification in medical records; ensure EHR templates include diagnosis coding for MDS (ICD-10: D46.x series), AML (C92.0x), BPDCN, PTCL, and MDS/MPN overlap syndromes. (4) Front desk and prior auth staff must verify member eligibility under BCBS Tennessee plans and confirm the specific indication meets coverage criteria. (5) Do NOT implement changes to systems until after 9/30/2026; flag this policy in your compliance calendar. Claims submitted before 9/30/26 should NOT require this prior auth. Failure to obtain prior authorization after effective date will result in claim denials for non-covered indications or those not meeting criteria.